Pre-clinical studies for oral enzyme replacement therapy in Pompe disease knockout mice with tobacco seeds expressing human GAA
Gene & Protein in Disease · 2025
DOI: 10.36922/gpd.1760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene & Protein in Disease, 2025. Verfasst von Frank Martiniuk und 19 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Genetic deficiency of acid a-glucosidase (GAA) results in Pompe disease (PD) encompassing four clinical subtypes of varying severity. Our objective is to develop an innovative and affordable approach for enzyme replacement therapy (ERT) through oral administration (Oral-ERT) to maintain a sustained therapeutic level of enzyme daily to improve treatment efficacy. Tobacco seeds contain the metabolic machinery compatible with mammalian glycosylation-phosphorylation. We have shown that transgenic tobacco seeds expressing human GAA (tobrhGAA) were enzymatically active and can correct the enzyme deficiency in cultured cells and in GAA knockout (GAAKO) mice administered IP. We have extended these studies in PD KO mice with ground tobrhGAA seeds. Briefly, in PD knockout mice, Oral-ERT with ground tobrhGAA seeds showed a significant reversal of fore-limb and hind-limb muscle weakness, increased motor coordination/balance/strength/mobility, improved spontaneous learning, increased GAA activity in tissues, reduced glycogen in tissues and negligible serum titers to GAA. Pharmacokinetics showed maximum serum GAA concentration at 8 – 10 h and peak urine excretion at 10 – 12 h post-administration. The tobrhGAA was taken up in PD fibroblast, lymphoid, and myoblast cells. Enzyme kinetics compared favorably to hGAA, plus alglucosidase alfa or other recombinant human GAAs for Km, Vmax, pH optima, thermal heat stability, and IC50 for inhibitors. The tobrhGAA in seeds was stable for 15 years at room temperature. Thus, Oral-ERT with ground tobrhGAA seeds is an innovative approach that overcomes some of the challenges of alglucosidase alfa-ERT and provides a more effective, safe, and significantly less expensive treatment.
Zitieren
APA
Martiniuk, F., Mack, A., Martiniuk, J., Voronin, G. O., Miller, S., Reimer, D., Rossi, N., Bird, L. S., Saleh, S., Gupta, R., Nigro, M., Meinke, P., Schoser, B., Wu, F., Kambitsis, A., Arvanitopoulos, J., Arvanitopoulos, E., Arvanitopoulos, P., Demetriades, A., & Tchou-Wong, K. (2025). Pre-clinical studies for oral enzyme replacement therapy in Pompe disease knockout mice with tobacco seeds expressing human GAA. Gene & Protein in Disease. https://doi.org/10.36922/gpd.1760
Vancouver
Martiniuk F, Mack A, Martiniuk J, Voronin GO, Miller S, Reimer D, et al. Pre-clinical studies for oral enzyme replacement therapy in Pompe disease knockout mice with tobacco seeds expressing human GAA. Gene & Protein in Disease. 2025. doi:10.36922/gpd.1760
BibTeX
@article{Martiniuk2025,
author = {Martiniuk, Frank and Mack, Adra and Martiniuk, Justin and Voronin, Gregory O. and Miller, Shoreh and Reimer, David and Rossi, Nancy and Bird, Leslie Sheppard and Saleh, Sussan and Gupta, Ruby and Nigro, Mariel and Meinke, Peter and Schoser, Benedikt and Wu, Feng and Kambitsis, Angelo and Arvanitopoulos, John and Arvanitopoulos, Elena and Arvanitopoulos, Pavlos and Demetriades, Alexander and Tchou-Wong, Kam-Meng},
title = {Pre-clinical studies for oral enzyme replacement therapy in Pompe disease knockout mice with tobacco seeds expressing human GAA},
journal = {Gene & Protein in Disease},
year = {2025},
doi = {10.36922/gpd.1760}
}
EUVIMED